Gerber Kawasaki Wealth & Investment Management trimmed its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 662 shares of the life sciences company’s stock after selling 40 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Illumina were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 39 shares during the period. Financial Advocates Investment Management increased its holdings in Illumina by 1,430.0% during the 4th quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 572 shares during the period. Proficio Capital Partners LLC increased its holdings in Illumina by 61.7% during the 4th quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 37 shares during the period. C J Advisory Inc bought a new stake in Illumina during the 1st quarter worth approximately $29,000. Finally, Lake Point Wealth Management bought a new stake in Illumina during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 89.70% of the company’s stock.
A number of analysts recently weighed in on ILMN shares. Canaccord Genuity reaffirmed a “buy” rating and set a $350.00 target price (down previously from $360.00) on shares of Illumina in a report on Friday, April 26th. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Tuesday, April 16th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target on the stock in a report on Friday, February 22nd. Wolfe Research started coverage on shares of Illumina in a report on Thursday, May 30th. They issued an “outperform” rating on the stock. Finally, OTR Global lowered shares of Illumina to a “positive” rating in a report on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and an average target price of $353.58.
Shares of Illumina stock traded up $16.93 during trading on Friday, reaching $335.49. The company’s stock had a trading volume of 1,298,234 shares, compared to its average volume of 788,645. Illumina, Inc. has a 52-week low of $268.62 and a 52-week high of $372.61. The stock has a market capitalization of $46.83 billion, a price-to-earnings ratio of 58.65, a price-to-earnings-growth ratio of 2.22 and a beta of 1.07. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company had revenue of $846.00 million during the quarter, compared to analysts’ expectations of $838.70 million. During the same quarter in the prior year, the company earned $1.45 EPS. The firm’s revenue was up 8.2% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.
In other news, SVP Charles Dadswell sold 124 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $314.45, for a total value of $38,991.80. Following the completion of the sale, the senior vice president now owns 8,210 shares of the company’s stock, valued at approximately $2,581,634.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $314.45, for a total transaction of $314,450.00. Following the sale, the director now directly owns 4,256 shares of the company’s stock, valued at approximately $1,338,299.20. The disclosure for this sale can be found here. Insiders sold a total of 49,031 shares of company stock valued at $15,232,996 in the last ninety days. 0.38% of the stock is owned by corporate insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: How to Invest in Marijuana Stocks
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.